Stockreport

Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See [Seeking Alpha]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF NDV-01 demonstrated a 76% 12-month complete response rate and favorable safety, supporting advancement into Phase 3 with two registrational pathways. RLMD secured ~$1 [Read more]